,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2020-09-28 10:50:00,Recently Amgen (NASDAQ:AMGN) stock was included on the Dow Jones index.,0.08566079288721085,0.01013826671987772,0.9042009115219116,neutral,0.0755225270986557
1,2020-09-28 10:50:00,The company joined two others: Salesforce.com (NYSE:CRM) and Honeywell (NYSE:HON).,0.05893854424357414,0.005850663874298334,0.9352108240127563,neutral,0.053087878972291946
2,2020-09-28 10:50:00,"While the Dow Jones index has its issues, it is still prestigious.",0.33285683393478394,0.03636618331074715,0.6307769417762756,neutral,0.2964906394481659
3,2020-09-28 10:50:00,Attaining this achievement was certainly not easy.,0.4236292839050293,0.026894638314843178,0.549476146697998,neutral,0.39673465490341187
4,2020-09-28 10:50:00,"Founded in the early 1980s, the company faced lots of tough challenges.",0.18928667902946472,0.04454708471894264,0.7661662697792053,neutral,0.14473959803581238
5,2020-09-28 10:50:00,Keep in mind that company had great difficulties in coming up with new drugs as well as raising enough capital for the R&D.,0.10844195634126663,0.19672757387161255,0.6948304772377014,neutral,-0.08828561753034592
6,2020-09-28 10:50:00,"But in the late 1980s, Amgen hit an inflection point.",0.29600289463996887,0.028024662286043167,0.6759724020957947,neutral,0.2679782211780548
7,2020-09-28 10:50:00,The company’s investments finally paid off in a big way.,0.8737426400184631,0.016424046829342842,0.1098332554101944,positive,0.8573185801506042
8,2020-09-28 10:50:00,"Amgen received FDA approval for the first recombinant human erythropoetin product, called Epogen, for anemia.",0.8496190309524536,0.01478672493249178,0.1355942040681839,positive,0.8348323106765747
9,2020-09-28 10:50:00,"Then there would be approval of Neupogen, for treating infections due to chemotherapy – which would become another blockbuster drug.",0.5126928687095642,0.011346987448632717,0.4759601056575775,positive,0.5013458728790283
10,2020-09-28 10:50:00,But this would be only the beginning of a long string of innovations and breakthroughs.,0.6326825618743896,0.01599619910120964,0.3513212203979492,positive,0.6166863441467285
11,2020-09-28 10:50:00,"As of now, Amgen has a market value of $23.4 billon and annual revenues of $145 billion.",0.02772511914372444,0.004845782183110714,0.9674291610717773,neutral,0.022879336029291153
12,2020-09-28 10:50:00,"Yes, it is a powerhouse in the biotech industry.",0.6102666258811951,0.011396546848118305,0.37833675742149353,positive,0.5988700985908508
13,2020-09-28 10:50:00,"So when thinking of investing in the company, what are some of the key factor to consider?",0.02476602979004383,0.006406465545296669,0.9688274264335632,neutral,0.018359564244747162
14,2020-09-28 10:50:00,"Well, let’s take a look at three:

Amgen has a long history of investing aggressively in R&D (last year the spending was a hefty $4 billion).",0.3065659999847412,0.008053095079958439,0.6853809356689453,neutral,0.29851290583610535
15,2020-09-28 10:50:00,The result is that the company has been building a solid portfolio of drugs.,0.9264863133430481,0.013315331190824509,0.060198329389095306,positive,0.9131709933280945
16,2020-09-28 10:50:00,Note that six generate more than $500 million a year.,0.08951187878847122,0.009860611520707607,0.9006274342536926,neutral,0.07965126633644104
17,2020-09-28 10:50:00,"• 7 Sin Stocks To Buy That Will Outperform the S&P 500

In 2019, Amgen launched EVENITY, which is an osteoporosis treatment that increases bone formation and lowers bone loss.",0.8486302495002747,0.01950662024319172,0.13186314702033997,positive,0.8291236162185669
18,2020-09-28 10:50:00,"Because of this, there is a reduced incidence of fracture.",0.675713300704956,0.023160137236118317,0.30112650990486145,positive,0.652553141117096
19,2020-09-28 10:50:00,Consider that about a third of women – who are over 50 – will have fractures because of osteoporosis.,0.05035732313990593,0.20446999371051788,0.7451726198196411,neutral,-0.15411266684532166
20,2020-09-28 10:50:00,"In fact, Amgen has other treatments for this disease, including Prolia.",0.08611416816711426,0.005540750455111265,0.908345103263855,neutral,0.0805734172463417
21,2020-09-28 10:50:00,"But when it comes to AMGN stock, the key is the pipeline.",0.043659746646881104,0.006194587331265211,0.9501456618309021,neutral,0.037465158849954605
22,2020-09-28 10:50:00,"Now it’s true that the company has had challenges with this, as has been the case with other large biotech operators.",0.18404832482337952,0.6105828881263733,0.2053687870502472,negative,-0.4265345633029938
23,2020-09-28 10:50:00,Yet it does look like Amgen stock is making progress.,0.9229899644851685,0.01555677317082882,0.061453286558389664,positive,0.9074332118034363
24,2020-09-28 10:50:00,Note that the company currently has more than 150 clinical trials for dozens of drug candidates.,0.1351231336593628,0.006990646943449974,0.8578862547874451,neutral,0.12813249230384827
25,2020-09-28 10:50:00,"They target areas include pediatric migraines, male osteoporosis, multiple myeloma, heart failure – just to name a few.",0.018228689208626747,0.018819095566868782,0.962952196598053,neutral,-0.0005904063582420349
26,2020-09-28 10:50:00,A point of leverage for AMGN stock has been a savvy acquisitions strategy.,0.6709005832672119,0.011911842040717602,0.3171875774860382,positive,0.6589887142181396
27,2020-09-28 10:50:00,"One of the most important deal was for Otezla, which is the only oral non-biologic treatment for psoriasis and psoriatic arthritis.",0.41230475902557373,0.009823859669268131,0.5778714418411255,neutral,0.4024809002876282
28,2020-09-28 10:50:00,"Last year, the sales reached about $2 billion.",0.1338651031255722,0.007375394459813833,0.8587594628334045,neutral,0.12648971378803253
29,2020-09-28 10:50:00,"There have also been some important partnerships, such as with Beigene (NASDAQ:BGNE).",0.5483713150024414,0.009010802023112774,0.44261786341667175,positive,0.539360523223877
30,2020-09-28 10:50:00,The company is the largest biotech operator in China.,0.3635215163230896,0.007769818417727947,0.6287086606025696,neutral,0.3557516932487488
31,2020-09-28 10:50:00,"Amgen, which got a 20.5% stake in the company, will be able to distribute its oncology drugs in the country.",0.7697531580924988,0.010422324761748314,0.21982461214065552,positive,0.7593308091163635
32,2020-09-28 10:50:00,"Finally, AMGN has the resources to continue its aggressive dealmaking.",0.9205994606018066,0.013449253514409065,0.06595130264759064,positive,0.9071502089500427
33,2020-09-28 10:50:00,The free cash flows are substantial – coming to $2.7 billion in the latest quarter.,0.9162838459014893,0.015956318005919456,0.06775980442762375,positive,0.9003275036811829
34,2020-09-28 10:50:00,Biotech remains a strong growth industry.,0.8209136724472046,0.01272120513021946,0.16636520624160767,positive,0.8081924915313721
35,2020-09-28 10:50:00,"According to Grand View Research, the spending is forecasted to increase by 7.4% to a whopping $727.1 billion by 2025.",0.9471376538276672,0.01573965698480606,0.03712264448404312,positive,0.9313979744911194
36,2020-09-28 10:50:00,"Here are some of the key drivers:
• Aging of the Global Population: The number of those 60 or over is expected to jump from 760 million to two billion.",0.8768646121025085,0.018990416079759598,0.10414494574069977,positive,0.8578742146492004
37,2020-09-28 10:50:00,"In other words, there will continue to be growing demand for health services.",0.8187331557273865,0.011943016201257706,0.1693238615989685,positive,0.8067901134490967
38,2020-09-28 10:50:00,• Lifestyle: The sedentary lifestyle and bad eating habits have meant that a rising number of people have become more susceptible to disease.,0.05137846618890762,0.8488569259643555,0.09976459294557571,negative,-0.797478437423706
39,2020-09-28 10:50:00,"• Digital Technologies: No doubt, biotech is more than experimenting with DNA.",0.13370749354362488,0.008794891647994518,0.8574976325035095,neutral,0.12491260468959808
40,2020-09-28 10:50:00,There have been great advances in leveraging AI (Artificial Intelligence) and ML (Machine Learning) to identify and test different treatments.,0.432487428188324,0.009219451807439327,0.5582931637763977,neutral,0.42326799035072327
41,2020-09-28 10:50:00,"• Regulation: For the most part, governments have become more willing to approve new treatments.",0.6868335604667664,0.014992768876254559,0.2981736958026886,positive,0.6718407869338989
42,2020-09-28 10:50:00,There are also various “orphan” programs that encourage the development of drugs for rare diseases.,0.0873841866850853,0.006540526635944843,0.9060752987861633,neutral,0.08084365725517273
43,2020-09-28 10:50:00,"Even with the growth in the biotech industry, the risks are still considerable.",0.1618061363697052,0.028097590431571007,0.8100963234901428,neutral,0.13370855152606964
44,2020-09-28 10:50:00,It’s common for new treatments to fail in clinical trials.,0.04782012104988098,0.7989997267723083,0.15318012237548828,negative,-0.751179575920105
45,2020-09-28 10:50:00,This is why investing in something like Amgen stock is a good approach because of the diverse portfolio of drugs and strong financial resources.,0.5699298977851868,0.00962971430271864,0.42044034600257874,positive,0.5603001713752747
46,2020-09-28 10:50:00,"On the date of publication, Tom Taulli did not have (either directly or indirectly) any positions in any of the securities mentioned in this article.",0.008334866724908352,0.024265868589282036,0.9673992395401001,neutral,-0.01593100279569626
47,2020-09-28 10:50:00,"Tom Taulli (@ttaulli) is an advisor/board member for startups and author of various books and online courses about technology, including Artificial Intelligence Basics, The Robotic Process Automation Handbook and Learn Python Super Fast.",0.05773615837097168,0.010725337080657482,0.9315385222434998,neutral,0.04701082035899162
48,2020-09-28 10:50:00,"He is also the founder of WebIPO, which was one of the first platforms for public offerings during the 1990s.",0.09341476857662201,0.006291873287409544,0.9002934098243713,neutral,0.08712289482355118
49,2020-09-28 10:50:00,"• Why Everyone Is Investing in 5G All WRONG
• Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company

The post 3 Reasons To Be Bullish On Biotech Giant Amgen appeared first on InvestorPlace.",0.2159619927406311,0.033575959503650665,0.7504620552062988,neutral,0.18238604068756104
